Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 11 » Issue 1

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease

Authors Matera MG, Sanduzzi A, Cazzola M

Received 17 July 2015

Accepted for publication 7 November 2015

Published 5 January 2016 Volume 2016:11(1) Pages 73—79


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Maria Gabriella Matera,1 Alessandro Sanduzzi,2 Mario Cazzola3

1Department of Experimental Medicine, Second University of Naples, 2Department of Respiratory Diseases, Monaldi Hospital, University Federico II, Naples, 3Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy

Abstract: Co-administration of a long-acting β2-agonist and a long acting muscarinic antagonist produces superior bronchodilation compared with their individual effects. Our preclinical data indicated that combining aclidinium bromide (ACLI) and formoterol fumarate (FORM) provides synergistic benefit on smooth muscle relaxation of both large and small human airways. Data from more than 2,000 patients in eleven clinical trials documented that ACLI/FORM, a twice-daily fixed-dose combination, produces a greater degree of bronchodilation than ACLI or FORM monotherapy alone and is safe and well tolerated. Two large key trials have shown that there is a benefit in using ACLI/FORM when the clinical target is the variability of symptoms and mainly nighttime and/or early morning symptoms. ACLI/FORM is the only long acting muscarinic antagonist/long acting β2-agonist fixed-dose combination that has been studied for this therapeutic indication.

Keywords: aclidinium, formoterol, fixed-dose combination, COPD, symptoms

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]